SCHEDULE: Asher Group Boosts Ekso Bionics Stake to 16.51% via Conversion

Daniel Asher and affiliated entities increased their beneficial ownership in Ekso Bionics Holdings, Inc. to 16.51% following a preferred share conversion.

Summary

• Daniel Asher, Daniel Asher Descendants Trust, and DBA Trading, LLC collectively reported beneficial ownership of Ekso Bionics Holdings, Inc. ordinary shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in previously reported ownership.
• On January 22, 2026, 2,926 preferred shares were converted into 355,960 ordinary shares at a conversion price of $1,000.00 per preferred share.
• Daniel Asher is deemed to control and share voting and dispositive power over the shares held by DBA Trading, LLC and Daniel Asher Descendants Trust.
• Daniel Asher's beneficial ownership stands at 677,723 ordinary shares, representing 16.51% of the class.
• The Daniel Asher Descendants Trust beneficially owns 355,960 ordinary shares, representing 8.67% of the class.
• DBA Trading, LLC beneficially owns 156,763 ordinary shares, representing 3.82% of the class.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While the conversion causes dilution, it also signifies a significant investor group's continued, albeit adjusted, commitment to the company's equity.

Positives

• A significant investor group, led by Daniel Asher, maintains a substantial stake in Ekso Bionics, potentially signaling long-term confidence in the company's prospects.

Negatives

• The conversion of preferred shares into common shares increases the number of outstanding common shares, leading to dilution for existing common shareholders.

Risks

• Dilution of existing common shareholders due to the increase in the number of ordinary shares outstanding from the conversion of preferred shares.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future operations or financial performance, focusing solely on beneficial ownership changes.

Industry Context

StockSavvy.ai notes that such conversions are common mechanisms for investors to realize gains or adjust their equity exposure. For a company in the bionics and robotics industry like Ekso Bionics, a significant investor group maintaining a large stake can be seen as a vote of confidence, though the dilution aspect needs to be considered in the context of market capitalization and future growth prospects compared to peers like ReWalk Robotics or Cyberdyne.

Comparison to Industry Standards

• The conversion of preferred shares to common stock is a standard financial mechanism, often seen when preferred shareholders exercise their rights, typically due to favorable market conditions or specific contractual triggers. This is a common practice across various industries, including medical devices and robotics, where early-stage investors often hold preferred stock.
• While the filing does not provide direct operational comparisons, the increase in common shares outstanding due to conversion is a factor that investors in growth-oriented companies like Ekso Bionics, ReWalk Robotics, or Bionik Laboratories must monitor, as it impacts per-share metrics.

Related Party Transactions

• Daniel Asher, who is the grantor of Daniel Asher Descendants Trust and beneficial owner of DBA Trading, LLC, is deemed to control and share voting and dispositive power over the shares held by these entities. The conversion of preferred shares into common shares by the Daniel Asher Descendants Trust is therefore a transaction involving related parties.

Stakeholder Impact

• Shareholders: Existing common shareholders experience dilution due to the increase in the number of outstanding ordinary shares from the conversion.
• Preferred Shareholders (converting): The Daniel Asher Descendants Trust, as a preferred shareholder, converted its preferred shares into common stock, altering its equity position and potentially its liquidity.

Next Steps

• The filing does not explicitly mention future actions or milestones by Ekso Bionics Holdings, Inc. or the reporting persons, beyond the completion of the share conversion.

Key Dates

Recommendation

The filing indicates a significant investor group's continued stake in Ekso Bionics through a preferred share conversion. While this demonstrates ongoing commitment, the resulting dilution for common shareholders warrants a 'hold' recommendation. Investors should monitor the impact of increased share count on per-share metrics and the company's future operational performance rather than making immediate buy or sell decisions based solely on this ownership change.

Keywords

Ekso Bionics Holdings, EKSO, Schedule 13G, Beneficial Ownership, Share Conversion, Daniel Asher, Institutional Investor, Dilution, Preferred Shares